Literature DB >> 11522179

Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?

J M Arduino1, M A Fischl, K Stanley, A C Collier, D Spiegelman.   

Abstract

Our objective was to assess whether HIV-1 RNA levels provide additional prognostic information beyond CD4(+) T lymphocyte counts in the prediction of subsequent HIV-1 disease progression among patients with advanced HIV-1 disease. In a nested case-control study conducted in patients with baseline CD4(+) T lymphocyte counts < 300 cells/mm(3) and receiving nucleoside reverse transcriptase inhibitors, 102 patients who progressed to an AIDS-defining event or death were matched within 10 CD4(+) T lymphocyte cells/mm(3) to patients who did not progress. The relationship between plasma HIV-1 RNA levels and HIV-1 disease progression was studied using conditional logistic regression analysis, which adjusts for the matching by baseline CD4(+) T lymphocytes. We observed a 0.10 log(10) copies/ml difference in baseline HIV-1 RNA levels between cases and their matched controls (p = 0.027). The relative risk for HIV-1 disease progression increased with increasing baseline HIV-1 RNA levels (odds ratio [OR] for a 3-fold higher HIV-1 RNA level, 1.42; 95% confidence interval [CI], 1.08--1.86), and remained important when also controlling for clinical status at baseline and CD4(+) T lymphocytes at 2 months (p = 0.038). Higher baseline HIV-1 RNA levels were associated with HIV-1 disease progression among patients with a baseline CD4(+) T lymphocyte count of 100 cells/mm(3) or greater (OR, 1.80; 95% CI, 1.15--2.81), but not among patients with a baseline CD4(+) T lymphocyte count < 100 cells/mm(3) (OR, 1.09; 95% CI, 0.73--1.63). We concluded that HIV-1 RNA levels predict subsequent HIV-1 disease progression independent of CD4(+) T lymphocyte counts. The magnitude and importance of the prognostic information contained in the HIV-1 RNA levels appear to depend on the CD4(+) T lymphocyte counts.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522179     DOI: 10.1089/088922201316912709

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

Review 1.  Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression.

Authors:  Kayvon Modjarrad; Eric Chamot; Sten H Vermund
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

2.  Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.

Authors:  Adam MacNeil; Abdoulaye Dieng Sarr; Jean-Louis Sankalé; Seema Thakore Meloni; Souleymane Mboup; Phyllis Kanki
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

3.  Approach to the management of paediatric HIV spontaneous controllers.

Authors:  Peter Zuidewind; Mark Cotton; Shaun Barnabas; Anita Janse Van Rensburg; Gert van Zyl; Carli Gordijn
Journal:  S Afr J Infect Dis       Date:  2022-06-30

4.  Effect of Immunomodulating Adjuvant Dzherelo (Immunoxel) in HIV Infected Patients Receiving Standard Antiretroviral Therapy.

Authors:  Lyudmila G Nikolaeva; Tatiana V Maystat; Yuri L Volyanskii; Volodymyr S Pylypchuk; Valery M Frolov; Galyna A Kutsyna
Journal:  Open Virol J       Date:  2009-05-05

5.  Predictors of disease progression in HIV infection: a review.

Authors:  Simone E Langford; Jintanat Ananworanich; David A Cooper
Journal:  AIDS Res Ther       Date:  2007-05-14       Impact factor: 2.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.